Clinical efficacy of acarbose in diabetes mellitus: A critical review of controlled trials

Diabetes and Metabolism

Volumn 24, Issue 4, 1998, Pages 311-321

  Scheen, A J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

glucosidase inhibitor; Dyslipidaemia; Glucose control; Hyperinsulinism; Postprandial; Type 1 diabetes; Type 2 diabetes

Indexed keywords

ACARBOSE; INSULIN; METFORMIN; PLACEBO; SULFONYLUREA;

CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES CONTROL; DIET THERAPY; DRUG EFFECT; DRUG EFFICACY; DYSLIPIDEMIA; ENZYME INHIBITION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERINSULINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROGNOSIS; REVIEW;

ACARBOSE; BLOOD GLUCOSE; CONTROLLED CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; SULFONYLUREA COMPOUNDS; TRISACCHARIDES;

EID: 0031657801     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1988, 35, 214-243.
2. Balfour JA, McTavish D. Acarbose - an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs, 1993, 46, 1025-1054.
3. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s : achievements and future developments. Drugs, 1997, 54, 355-368.
4. Brendel E, Wingender W. Clinical pharmacology of glucosidase inhibitors. In : Kuhlmann J, Puls W, eds. "Oral antidiabetics. Handbook of Experimental Pharmacology". Berlin : Springer Verlag, 1995, 611-632.
5. Creutzfeldt W, ed. Proceedings of the First International Symposium on Acarbose. Acarbose. Effects on carbohydrate and fat metabolism. Amsterdam : Excerpta Medica, 1982.
6. Creutzfeldt W, ed. Proceedings of the Second International Symposium on Acarbose. Acarbose for the treatment of diabetes mellitus. Berlin : Springer Verlag, 1988.
7. Lefèbvre PJ, Standl E, eds. New aspects in diabetes. Treatment strategies with alpha-glucosidase inhibitors. Berlin, New York : de Gruyter, 1992.
8. Chiasson J-L, Gerich JE (eds). α-glucosidase inhibitors : a new therapeutic option in diabetes mellitus. Drugs, 1992, 44 (Suppl 3), 1-65.
9. Dimitradis G, Raptis S. α-glucosidase inhibition in the treatment of diabetes mellitus. Horm Metabol Res. 1992, 26 (Suppl), 42-49.
10. Nieuwenhuijzen Kruseman AC, Sels JPJE, Wolffenbuttel BHR, editors. α-glucosidase inhibitors in diabetes. Eur J Clin Invest, 1994, 24 (Suppl 3), 1-54.
11. Lerman I, Gomez Pérez FJ, Aguilar-Salinas CA, Rull Rodrigo JA. Acarbose : in search for its real indications in current medical practice. Diabetes Care, 1996, 19, 94-95.
12. Berger M, Köbberling J, Windeler J. Appraisal of effectiveness and potential therapeutic benefit of acarbose : a non-consensus conference. Diabetologia, 1996, 39, 873-874.
13. Riddle MC. Tactics for type II diabetes. Endocrinol Metab Clin North Am, 1997, 26, 659-677.
14. Scheen AJ, Lefèbvre PJ. Oral antidiabetic drugs : a guide to selection. Drugs. 1998, 55, 225-236.
15. Santeusanio F, Compagnucci P. A risk-benefit appraisal of acarbose in the management of non-insulin-dependent diabetes mellitus. Drug Safety, 1994, 11, 432-444.
16. Taylor RH, Bardoplh EM. Clinical evaluation of glucosidase inhibitors. In : Kuhlmann J, Puls W, eds. "Oral antidiabetics. Handbook of Experimental Pharmacology". Berlin : Springer Verlag, 1996, 633-649.
17. Salvatore T, Giugliano D. Pharmacokinctic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet, 1996, 30, 94-106.
18. Meng-Hee Tan. α-glucosidase inhibitors in the treatment of diabetes. Curr Opin Endocrinol Diab, 1997, 4, 48-55.
19. Scheen AJ. Place de l'acarbose dans le traitement du diabète sucré. Diab Metab, 1998, 24, pages à indiquer (même no).
20. Baron A, Neumann C, on behalf of the PROTECT Study Group. PROTECT interim results : a large multicenter study of patients with type II diabetes. Clin Ther. 1997, 19, 282-295.
21. Spengler M,. Cagatay M. The use of acarbose in the primary-care setting : evaluation of efficacy and tolcrability of acarbose by post-marketing surveillance study. Clin Invest Med, 1995, 18, 325-331.
22. Toeller M. Dietary treatment and α-glucosidase inhibitors in NIDDM. Diabetes Nutr Metab, 1990, 3 (Suppl), 43-49.
23. Hara T, Nakamura J, Koh N, Sakakihara F, Takeuchi N, Hotta N. An importance of carbohydrate ingestion for the expression of the effect of α-glucosidase inhibitor in NIDDM. Diabetes Care, 1996, 19, 642-647.
24. Holman RR, Cull CA, Turner RC. Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients (Abstract). Diabetologia, 1996, 39 (Suppl 1), A44.
25. Fölsch UR. Clinical experience with acarbose as first line therapy in NIDDM. Clin Invest Med, 1995, 18, 312-317.
26. Buchanan DR, Collier A, Rodrigucs E, Millar AM, Gray RS, Clarke BF. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin-dependent diabetes. Eur J Clin Pharmacol, 1988, 34, 51-53.
27. Hanefeld M, Fischer S, Schulze J et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care, 1991, 14, 732-737.
28. Hotta N, Kakuta H, Sano T et al. Long-term effect of acarbose on glycaemic control in non-insulin-dependent diabetes mellitus : a placebo-controlled double-blind study. Diabetic Med, 1993, 10, 134-138.
29. Santcusanio F, Ventura MM, Contadini S et al. Efficacy and safety of two different dosages of acarbose in non-insulin-dependent diabetic patients treated by diet alone. Diab Nutr Metab. 1993, 6, 147-154.
30. Chiasson JL, Josse RG, Hunt JA et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus : a multicenter controlled clinical trial. Ann Intern Med. 1994, 121, 928-935.
31. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients : the Essen study. Diabetes Care, 1994, 17, 561-566.
32. Coniff RF, Shapiro JA, Seaton TB. Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus. Arch Intern Med, 1994, 154, 2442-2448.
33. Coniff RF, Shapiro JA, Robbins D et al. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NTDDM : a placebo-controlled dose-comparison study. Diabetes Care, 1995, 18, 817-824.
34. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ et al. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus. A controlled, double blind comparison study with placebo. Diab Metab, 1996, 22, 201-202.
35. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in NIDDM patients with diet failure (Abstract). Diabetologia, 1996, 39 (Suppl 1), A230.
36. Fölsch UR, Spengler M, Boehme K, Sommerauer B. Efficacy of glucosidase inhibitors compared to sulphonylureas in the treatment and metabolic control of diet treated type II diabetic subjects : two long-term comparative studies. Diab Nutr Metab, 1990, 3 (Suppl 1), 63-68.
37. Spengler M, Hansel G, Bochme K. Efficacy of 6 months monotherapy with glucosidase inhibitor Acarbose versus sulphonylurea glibenclamide on metabolic control of dietary treated type II diabetics (NTDDM). Horm Metabol Res, 1992, 26 (Suppl), 50-51.
38. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med, 1995, 98, 443-451.
39. Van Gaal L, Nobels F, de Leeuw I. Effects of acarbose on carbohydrate metabolism, electrolytes, minerals and vitamins in fairly well-controlled non-insulin-dependent diabetes mellitus. Z Gastroenterol, 1991, 29, 642-644.
40. Gomez-Perez FJ, Violante R, Sanchez-Arriaga LF, Wong B, Rull JA. Eficacia y tolerancia de acarbose en pacientes diabeticos no dependientes de insulina. Rev Invest Clin, 1992, 44, 77-83.
41. Wilms B. Therapie des Typ-11-Diabetes - α-Glucosidasehemmer (Acarbose). Akt Endokr Stoffw, 1992, 13, 51-56.
42. de Leiva A, Pinon P, Tebar J et al., Efficacia clinica y tolerancia de la acarbosa en et tratamiento de pacientes diabeticos no dependientes de la insulina (tipo II). Med Clin (Barcelona), 1993, 100, 368-371.
43. May C. Efficacy and tolerability of stepwise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM), treated with sulphonylureas. Diabetes und Stoffwechsel, 1995, 4, 3-8.
44. Schöffling K, Petzoldt R, Hillebrand I, Schwedes U. Comparison of metformin and acarbose treatment in non-insulin-dependent diabetics (NIDDM). A double-blind cross-over study. In : Genetic Environmental Interaction in Diabetes Mellitus. Melish, Hanna & Baba, eds. Amsterdam - Oxford - Princeton, Excerpta Medica, 1982, 339-343.
45. Johansen K. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an α-glucosidase inhibitor with metformin. Diab Metab, 1984, 10, 219-223.
46. Calle-Pascual A, Garcia-Honduvilla J, Martin-Alvarez PJ et al. Comparison between acarbose, metformin and insulin treatment in type 2 diabetic patients with secondary failure to sulfonylurea treatment. Diab Metab, 1995, 21, 256-260.
47. Bayraktar M, Van Thiel DH, Adalar N. A comparison of acarbose versus metformin as an adjunct therapy in sulfonylurea-treated NIDDM patients. Diabetes Care, 1996, 19, 252-254.
48. Pagano G, Cavallo-Perin P. Glucosidase inhibitors and biguanides in the treatment of non-insulin-dependent diabetic patients. Diabetes Nutr Metab, 1990, 3 (Suppl 1), 69-76.
49. Hanefeld M, Bär K, Mertes G, Berlinghoff R. Metformin improves metabolic control in non-insulin-dependent diabetics with acarbose monotherapy (Abstract). Diabetologia, 1997, 40 (Suppl 1), A312.
50. Scheen AJ, Ferreira Alves de Magalhaes AC, Salvatore T et al. Reduction of the acute bioavailability of metformin by the alpha-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest, 1994, 24 (Suppl 3), 50-54.
51. Rodier M, Richard JL, Monnier L, Mirouze J. Effect of long term acarbose (Bay g 5421) therapy on metabolic control of non-insulin-dependent (type II) diabetes mellitus. Diab Metab, 1988, 14, 12-14.
52. Vannasaeng S, Ploybutr S, Nitiyanant W, Peerapatdit T, Vichayanrat A. Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus. J Med Assoc Thai, 1995, 78, 578-585.
53. Kaye TB. Triple oral anti-diabetic therapy. Diabetes, 1997, 46 (Suppl 1), 290A.
54. Hotta N, Kakuta H, Koh N et al. The efffects of acarbose on blood glucose profiles of type 2 diabetic patients receiving insulin therapy. Diabetic Med, 1993, 10, 355-358.
55. Rybka J, Gegorova A, Zmydlena A, Jaron P. Clinical study of acarbose. Drug Invest, 1990, 2, 264-267.
56. Coniff RF, Shapiro JA, Seaton TB et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care, 1995, 18, 928-932.
57. Standl E, Baumgartl HJ, Fuechtenbusch M, Stemplinger J. Effect of acarbose on additional insulin therapy of type II diabetics with late failure of sulphonylurea therapy. Diabetes, 1997, 46 (Suppl 1), 294A.
58. Gérard J, Luyckx A, Lefèbvre P. Improvement of metabolic control in insulin-dependent diabetics treated with the α-glucosidase inhibitor acarbose for two months. Diabetologia, 1981, 21, 446-451.
59. Tattersall R. α-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes. Diabetic Med, 1993, 10, 688-693.
60. Rios MA. Acarbose and insulin therapy in type I diabetes mellitus. Ear J Clin Invest, 1994, 24 (Suppl 3), 36-39.
61. Viviani GL, Camogliano L, Borgoglio MG, Ohnmeiss H, Adezati L. Acarbose treatment in insulin-dependent diabetics - a double-blind crossover study. Curr Ther Res Clin Exp, 1987, 42, 1-11.
62. Marena S, Tagliaferro V, Cavallero G et al. Double-blind crossover study of acarbose in type 1 diabetic patients. Diabetic Med, 1991, 8, 674-678.
63. Austenat E. Neuere Therapiestudien mit Acarbose bei Typ-1-Diabetikern. Akt Endokr Stoffw, 1991, 12, 19-24.
64. Escobar-Jimenez F, de Leiva A, Pinon P et al. Efficacia clinica y tolerancia de la acarbosa en et tratamiento de pacientes diabeticos dependientes de la insulina (tipo I). Med Clin (Barcelona), 1993, 100, 488-491.
65. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type 1 diabetes. Diabetes Care, 1997, 20, 248-253.
66. McCulloch DK, Kurtz AB, Tattersall RB. A new approach to the treatment of nocturnal hypoglycemia using α-glucosidase inhibition. Diabetes Care, 1983, 6, 483-487.
67. Lefèbvre PJ, Scheen AJ. The postprandial state and the risk of cardiovascular disease. Diabetic Med, 1998, in press.
68. Baron AD, Eckel RH, Schmeiser L, Kolterman OG. The effect of short term alpha glucosidase inhibition on carbohydrate and lipid metabolism in type II (non-insulin-dependent) diabetics. Metabolism, 1987, 35, 409-415.
69. Reaven GM, Lardinois CK, Greenfield MS, Schwartz HC, Vreman HJ. Effect of acarbose on carbohydrate and lipid metabolism in NIDDM patients poorly controlled by sulfonylureas. Diabetes Care, 1990, 13 (Suppl 3), 32-36.
70. Leonhardt W, Hanefeld M, Fischer S, Schulze J, Spengler M. Beneficial effects on serum lipids in non-insulin-dependent diabetics by acarbose treatment. Arzneimittelforschung, 1991, 41, 735-738.
71. Leonhardt W, Hanefeld M, Fischer S, Schulze J. Efficacy of α-glucosidase inhibitors on lipids in NIDDM with moderate hyperlipidaemia. Eur J Clin Invest, 1994, 24 (Suppl 3), 45-49.
72. Hegele RA, Connelly PW, Palmason C, Jenkins DJA, Wolever TMS. Differential responses of plasma lipoprotein(a) and apolipoprotein B in NIDDM subjects treated with acarbose. Diabetes Care, 1995, 18, 272-273.
73. Jenney A, Proietto J, O'Dea K, Nankervis A, Trainedes K, D'Embden H. Low dose acarbose improves glycemic control in NIDDM patients without changes in insulin sensitivity. Diabetes Care, 1993, 16, 499-502.
74. Chiasson JL, Josse RG, Leiter LA et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care, 1996, 19, 1190-1193.
75. Scott R, Lintot C. Acarbose improves the metabolic environment of NIDDM patients with plurimetabolic syndrome. Diabetes, 1997, 46 (Suppl 1), 294A.
76. Ceriello A, Taboga C, Tonutti L et al. Post-meal coagulation activation in diabetes mellitus : the effect of acarbose. Diabetologia, 1996, 39, 469-473.
77. Wolffenbuttel BH, van Haeften TW. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM). Drugs, 1995, 50, 263-288.
78. Zimmerman BR. Preventing long-term complications. Implications for combination therapy with acarbose. Drugs, 1992, 44 (Suppl), 54-60.
79. Fisher S, Hanefeld M, Spengler M, Boehme K, Temelkova-Kurktschiev T. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus : efficacy and safety of low and high doses. Acta Diabol, 1998, 44, 34-40.